Regístrese
¿Aún no está registrado?
Información relevante

Consulte los artículos y contenidos publicados en éste medio, además de los e-sumarios de las revistas científicas en el mismo momento de publicación

Máxima actualización

Esté informado en todo momento gracias a las alertas y novedades

Promociones exclusivas

Acceda a promociones exclusivas en suscripciones, lanzamientos y cursos acreditados

Crear Mi cuenta
Buscar en
Revista Médica del Hospital General de México
Toda la web
Inicio Revista Médica del Hospital General de México Pattern of differential expression of costimulatory molecules in myeloma cell li...
Journal Information
Vol. 81. Num. 4.October - December 2018
Pages 177-282
Share
Share
Download PDF
More article options
Visits
347
Vol. 81. Num. 4.October - December 2018
Pages 177-282
Original Article
DOI: 10.1016/j.hgmx.2016.08.005
Open Access
Pattern of differential expression of costimulatory molecules in myeloma cell line MM1.R
Patrón diferencial de expresión de moléculas coestimuladoras en la línea celular de mieloma MM1.R
Visits
347
A. De la Cruz-Rosasa, A. Martínez-Tovara, C. Ramos-Peñafielb, J. Collazo-Jalomac, I. Olarte-Carrilloa,
Corresponding author
irmaolartec@yahoo.com

Corresponding author at: Hospital General de México “Dr. Eduardo Liceaga”, Dr. Balmis 148, Col. Doctores, Del. Cuauhtémoc, C.P. 06726 Mexico City, Mexico.
a Molecular Biology Laboratory U-204, Department of Haematology, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City, Mexico
b Cancer Unit U-111, Department of Haematology, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City, Mexico
c Haematology Laboratory U-204, Department of Haematology, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City, Mexico
This item has received
347
Visits

Under a Creative Commons license
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Tables (1)
Table 1. Amplification sequences and conditions used.
Abstract

T cells constantly recognise and eliminate circulating tumour cells. They require two signals in order to be activated: antigen presentation via TCR, and costimulatory interaction with different surface molecules of the B7 family, which may either enhance or attenuate immune response. In several cancers these molecules are deregulated, thereby promoting immune escape and the settlement or migration of cancer cells. In multiple myeloma, the expression of B7 co-inhibitory molecules and their relationship to disease progression have been identified. The MM1.R cell line is a useful cellular model for studying the progression of this disease, and therefore an analysis of the pattern of expression in this cell line helps to cast light on the immune status of this disease. Using a real-time PCR (quantitative RT-PCR) assay, we found that the main molecules expressed were those with an inhibitory function (B7-H1, B7-H3 and B7-H4), which suggests a high level of immune inhibition by these cells.

Keywords:
Multiple myeloma
MM1.R
Costimulatory molecules
B7
PCR
Resumen

El reconocimiento y eliminación constante de células tumorales circulantes se logra principalmente mediante la acción de los linfocitos T, células cuya activación requiere de dos señales para poder llevarse a cabo: la presentación del antígeno a través del TCR y una interacción co-estimuladora liderada por distintas moléculas de superficie de la familia B7 que pueden potenciar o atenuar la respuesta. En varios tipos de cáncer, estas moléculas se encuentran desreguladas, favoreciendo el escape inmunológico y el asentamiento y/o migración de las células neoplásicas. En mieloma múltiple se ha identificado la expresión de moléculas B7 co-inhibitorias y su relación con la progresión de la enfermedad. La línea celular MM.1R es un modelo celular útil para estudiar la progresión de esta enfermedad, por lo que el análisis del patrón de expresión en esta línea celular contribuye a entender el estado inmunológico en la enfermedad. Mediante un ensayo de RT-PCR en tiempo real (qRT-PCR) encontramos que las moléculas mayormente expresadas fueron aquellas con función inhibitoria (B7H1, B7H3 y B7H4), lo cual indica una alta inhibición inmunológica por parte de estas células.

Palabras clave:
Mieloma múltiple
MM1.R
Coestimuladoras
B7
PCR
Full Text
Introduction

One of the main features of the immune system is immune surveillance, which is characterised by the system recognising and eliminating circulating tumour cells, thus preventing cancer from developing.1–4 In the immune system, T cells are primarily responsible for immune surveillance, activating apoptosis in neoplastic, senescent or undifferentiated cells.5,6 For T cells to be activated, two major signals are needed: recognition of an antigen bound to MHC molecules via their TCR, and a second costimulatory signal transmitted by the interaction of B7-CD28 in T cells.7 However, some neoplastic cells (bladder, colon, liver, lung, ovary, thyroid, kidney, sarcoma and melanoma) escape the immune system because they express surface molecules with inhibitory functions, thus causing T cell clonal anergy and evading elimination by the immune system.8–12 Negative costimulatory molecules in the B7 family are overexpressed in various cancers, and this overexpression is related to immune tolerance and disease progression.13–15 In multiple myeloma, the expression of these negative costimulatory molecules and their relationship to disease progression have been reported.16–18 The use of cellular models enables us to analyse gene expression in a more efficient and controlled manner. Therefore, in order to evaluate the pattern of expression of several members of the family of costimulatory molecules in this disease, we decided to use a cell line derived from the MM1.R multiple myeloma cell line (IgA multiple myeloma resistant to dexamethasone). The results showed a greater negative differential expression of costimulatory molecules and higher expression levels of B7-H3 and B7-H4.

Material and methodsCell culture

An MM1.R myeloma (IgA) cell line in RPMI/10% FBS medium was cultured in CO2 atmosphere (5%). Once expanded, a volume amount equivalent to a cell concentration of 106 cells was taken, and they were placed in culture plates (6 wells) with a total volume of 3ml. After one day, the cells were collected and stored until use at −80°C.

Total RNA extraction

Total RNA from the MM1.R cell line was isolated by TRIzol® (Invitrogen, Life Technologies) according to the manufacturer's instructions. The concentration and purity of the total RNA was measured by ultraviolet-visible spectrophotometry (Thermo Scientific, GENESYS™ 10S UV-Vis). The integrity of genetic material was confirmed via agarose gel electrophoresis (1.5%) for 40′ at 70 v. The RNA was stored at −80°C until it was needed.

cDNA synthesis and real-time PCR

cDNA synthesis was performed using 4μg of RNA, previously quantified by UV–Vis (Thermo Scientific, GENESYS™ 10S UV-Vis), 1μg of Oligo(dT) (Promega, Madison, WI, USA) and 200U of M-MLV (Promega, Madison, WI, USA).

The PCR assays were performed using a MultiGene™ OptiMax thermal cycler (Labnet). The constitutive genes GAPDH and β2 microglobulin were used as an internal reaction control. Included for the characterisation were genes belonging to the following costimulatory molecules: B7-1, B7-2, B7-H1, B7-H2, B7-H3, B7-H4 and B7-H6. Table 1 shows the primers and product length of each gene and the amplification conditions.

Table 1.

Amplification sequences and conditions used.

Primer  Sequence  Product length  Amplification conditions 
GAPDH forward  CGGGAAGCTTGTCATCAATGG  221pb  96°C – 45s
55°C – 45s
72°C – 45s
30 cycles 
GAPDH reverse  CATGGTTCACACCCATGACG     
β2-MG  CCTCCATGATGCTGCTTACATGTC  221pb  96°C – 45s
55°C – 45s
72°C – 45s
30 cycles 
β2-MG  ATGTCTCGCTCCGTGGCCTTAGCT     
B7-1 forward  CCTCTCCATTGTGATCCTGG  566pb  96°C – 1min
55°C – 45s
72°C – 1min
35 cycles 
B7-1 reverse  GGCGTACACTTTCCCTTCTC     
B7-2 forward  GACCTGCTCATCTATACAC  464pb  96°C – 1min
55°C – 45s 72°C – 1min
30 cycles 
B7-2 reverse  CTTCATCAGATCTTTCAGG     
B7-H1 forward  ACTGGCATTTGCTGAACGCA  301pb  96°C – 1min
57°C – 45s
72°C – 1min
35 cycles 
B7-H1 reverse  TACACCCCTGCATCCTGCAAT     
B7-H2 forward  GCAAACCAGTGAGTCGAAAACC  102pb  96°C – 1min
60°C – 45s
72°C – 1min
35 cycles 
B7-H2 reverse  GGTGACATCAGGGCTCGGT     
B7-H3 forward  AGCACTGTGGTTCTGCCTCACA  172pb  96°C – 1min
53°C – 45s
72°C – 1min
35 cycles 
B7-H3 reverse  CACCAGCTGTTTGGTATCTGTCAG     
B7-H4 forward  TTAGGCTTGGTCCATGAGTTCA  143pb  96°C – 1min
62°C – 45s
72°C – 1min
35 cycles 
B7-H4 reverse  TCTGTGAGTTGCACGTTTTTCAG     
B7-H6 forward  GACCCTGGGACTGTCTACCA  143pb  96°C – 1min
55°C – 45s
72°C – 1min
35 cycles 
B7-H6 reverse  ATAGGCCACCAATGAATGGA     
Quantitative RT-PCR

The mRNA levels of the genes B7-2, B7-H1, B7-H3 and B7-H4 were measured using an assay with SYBR Green (Applied Biosystems, Foster City, CA, USA). GAPDH was used as a control gene, with all the samples analysed in triplicate in each reaction. The assay was also performed with a negative control in order to assess any contamination of the reagents. Relative levels of gene expression were calculated using the 2−ΔΔCT method, with a sample of normal bone marrow as a calibrator. The median was used as the cut-off between high and low expression.

ResultsExpression of costimulatory molecules in cell line MM1.R through RT-PCR

The expression of genes that code for costimulatory molecules B7-1, B7-2, B7-H1, B7-H2, B7-H3, B7-H4 and B7-H6 in the multiple myeloma cell line MM1.R was analysed through endpoint RT-PCR. The results showed that there was only expression of one of the positive costimulatory genes (B7-2). Otherwise, 3 genes with inhibitory effects (B7-H1, B7-H3 and B7-H4) were expressed (Fig. 1).

Figure 1.
(0.04MB).

Characterisation panel in cell line MM1.R. The amplification pattern for the genes analysed (cell line MM1.R) is shown: B7-1 (566pb), B7-2 (464pb), B7-H1 (301pb), B7-H2 (102pb), B7-H3 (172pb), B7-H4 (143pb), B7-H6 (143pb). MWM: molecular weight marker. B2MG: β2 microglobulin.

Levels of expression of costimulatory molecules in cell line MM1.R through quantitative RT-PCR

From the pattern of expression previously analysed, the relative expression levels of genes B7-2, B7-H1, B7-H3, B7-H4 were analysed in cell line MM1.R by quantitative RT-PCR. The results showed reduced expression of costimulatory molecules B7-2 and B7-H1 and increased expression of B7-H3 and B7-H4 compared with the control (Graphs 1 and 2).

Graph 1.
(0.05MB).

Relative expression for genes B7-2 and B7-H1 in cell line MM1.R compared with healthy sample. Quantification method: ΔΔCT.

Graph 2.
(0.05MB).

Relative expression for genes B7-H3 and B7-H4 in cell line MM1.R compared with healthy sample. The graph shows a logarithmic scale with base 10. Quantification method: ΔΔCT.

Discussion

Costimulatory molecules are part of a system of secondary signalling mechanisms that are vital for maintaining the delicate balance between immunological potency and autoimmunity suppression.19 By interacting with ligands in the effector cells in immune responses, these transmembrane proteins trigger the stimulation or inhibition effects of this response. Tumour cells use deregulation of the expression of these molecules on their surfaces to carry out immune evasion, which involves the cell death of cytotoxic T cells and the recruitment of regulatory T cells.20–21

An analysis of the expression of these molecules in the cell line showed evidence that these cells have developed mechanisms of immune evasion, as with B7-H1 (PD-L1/CD273).22 The molecule B7-H1 is part of the most widely studied co-inhibitory pathway. In this way, the B7-H1/PD-1 pathway indirectly causes the death of effector cells and, therefore, a reduction in immune response.23,24

Another gene involved in generating immune inhibition mechanisms whose expression was confirmed in MM1.R cells was B7-H4 (B7x/B7S1/VTCN1). This is a co-inhibitory molecule whose interaction with its receptor decreases the proliferation and production of cytokines in CD4+ and CD8+ cells, as well as the expansion of neutrophil progenitors. Likewise, overexpression has been associated with different types of tumour, such as breast cancer, renal cancer, ovarian cancer and oesophageal carcinoma, amongst others.25–27 In multiple myeloma, this molecule has not been studied. However, as it is an important mechanism of immune evasion, it is highly likely to be expressed in this pathology. The discovery of this gene in cell line MM1.R concurs with what has been reported in other cancers, because, as mentioned above, the presence and overexpression of this gene has been associated with disease progression. Cell line MM1.R comes from an individual with an advanced stage of the disease (extramedullary); therefore, the finding of B7-H4 is a logical fact.

In addition to inhibitory B7-H1 and B7-H4 genes, two genes were found whose action differs depending on the receptor to which it binds. One of these two genes is B7-2 (CD86), which is part of the costimulatory/co-inhibitory pathway that is the most important in secondary signalling in mounting an immune response. The other gene identified in this assay was B7-H3, which codes for a type 1 transmembrane protein and which on a transcript level is widely expressed in lymphoid and non-lymphoid organs. However, its expression at the protein level is limited to recently activated monocytes, T cells, B cells and NK cells. High levels of expression are aberrant in this gene, and have been associated with conditions of cellular stress, such as cancer or sepsis.28–30 With regard to this molecule, both stimulatory and inhibitory functions have been reported, and to date, specific receptors for this ligand have not been conclusively identified.

The identification of these molecules helps to provide an overview of immune status in this disease. Similarly, these molecules represent alternative therapeutic molecular targets to traditional treatments, such as glucocorticoids, to which myeloma cells generate resistance during disease progression.

Ethical disclosureProtection of human and animal subjects

The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data

The authors declare that no patient data appear in this article.

Right to privacy and informed consent

The authors declare that no patient data appear in this article.

Funding

Resources facilitated by Hospital General de México's Research Department, registration number DIC/09/204/03/131, DIC/08/204/04/017.

Conflicts of interest

The authors declare that they have no conflicts of interest.

References
[1]
S. Ceeraz, E.C. Nowak, R.J. Noelle
B7 family checkpoint regulators in immune regulation and disease
Trends Immunol, 34 (2013), pp. 556-563 http://dx.doi.org/10.1016/j.it.2013.07.003
[2]
M.E. Keir, M.J. Butte, G.J. Freeman
PD-1 and its ligands in tolerance and immunity
[3]
P. Greaves, J.G. Gribben
The role of B7 family molecules in hematologic malignancy
[4]
M.F. Flajnik, T. Tlapakova, M.F. Criscitiello
Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHC
Immunogenetics, 64 (2012), pp. 571-590 http://dx.doi.org/10.1007/s00251-012-0616-2
[5]
A. Viola, A. Lanzavecchia
T cell activation determined by T cell receptor number and tunable thresholds
Science, 273 (1996), pp. 104-106
[6]
L.H. Boise, A.J. Minn, P.J. Noel
CD28 co-stimulation can promote T cell survival by enhancing the expression of Bcl-XL
Immunity, 3 (1995), pp. 87-98
[7]
I.C. Rulifson, A.I. Sperling, P.E. Fields
CD28 co-stimulation promotes the production of Th2 cytokines
J Immunol, 158 (1997), pp. 658-665
[8]
T.L. Walunas, D.J. Lenschow, C.Y. Bakker
CTLA-4 can function as a negative regulator of T cell activation
Immunity, 1 (1994), pp. 405-413
[9]
R.J. Greenwald, G.J. Freeman, A.H. Sharpe
The B7 family revisited
Rev Immunol, 23 (2005), pp. 515-548
[10]
M.M. Swallow, J.J. Wallin, W.C. Sha
B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNF alpha
Immunity, 11 (1999), pp. 423-432
[11]
A. Hutloff, A.M. Dittrich, K.C. Beier
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Nature, 397 (1999), pp. 263-266 http://dx.doi.org/10.1038/16717
[12]
Y.S. Choi, R. Kageyama, D. Eto
ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6
[13]
A.I. Chapoval, J. Ni, J.S. Lau
B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production
Nat Immunol, 2 (2001), pp. 269-274 http://dx.doi.org/10.1038/85339
[14]
G. Zhang, J. Wang, J. Kelly
B7-H3 augments the inflammatory response and is associated with human sepsis
J Immunol, 185 (2010), pp. 3677-3684 http://dx.doi.org/10.4049/jimmunol.0904020
[15]
M. Hashiguchi, H. Kobori, P. Ritprajak
Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses
Proc Natl Acad Sci U S A, 105 (2008), pp. 10495-10500 http://dx.doi.org/10.1073/pnas.0802423105
[16]
J. Leitner, C. Klauser, W.F. Pickl
B7-H3 is a potent inhibitor of human T-cell activation: no evidence for B7-H3 and TREML2 interaction
Eur J Immunol, 39 (2009), pp. 1754-1764 http://dx.doi.org/10.1002/eji.200839028
[17]
X. Zang, P. Loke, J. Kim
B7x: a widely expressed B7 family member that inhibits T cell activation
Proc Natl Acad Sci U S A, 100 (2003), pp. 10388-10392 http://dx.doi.org/10.1073/pnas.1434299100
[18]
X. Wang, J. Hao, D.L. Metzger
B7-H4 treatment of T cells inhibits ERK, JNK, p38, and AKT activation
[19]
X. Wang, J. Hao, D.L. Metzger
Local expression of B7-H4 by recombinant adenovirus transduction in mouse islets prolongs allograft survival
Transplantation, 87 (2009), pp. 482-490 http://dx.doi.org/10.1097/TP.0b013e318195e5fa
[20]
C. Chen, Y.B. Zhu, Y. Shen
Increase of circulating B7-H4-expressing CD68+ macrophage correlated with clinical stage of lung carcinomas
J Immunother, 35 (2012), pp. 354-358 http://dx.doi.org/10.1097/CJI.0b013e31824212c4
[21]
L.J. Chen, J. Sun, H.Y. Wu
B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma
Cancer Immunol Immunother, 60 (2011), pp. 1047-1055 http://dx.doi.org/10.1007/s00262-011-1017-3
[22]
D. Quandt, E. Fiedler, D. Boettcher
B7-h4 expression in human melanoma: its association with patients’ survival and antitumor immune response
Clin Cancer Res, 17 (2011), pp. 3100-3111 http://dx.doi.org/10.1158/1078-0432.CCR-10-2268
[23]
L. Wang, R. Rubinstein, J.L. Lines
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
J Exp Med, 208 (2011), pp. 577-592 http://dx.doi.org/10.1084/jem.20100619
[24]
M.A. Sakr, T. Takino, T. Domoto
GI24 enhances tumor invasiveness by regulating cell surface membrane-type 1 matrix metalloproteinase
Cancer Sci, 101 (2010), pp. 2368-2374 http://dx.doi.org/10.1111/j.1349-7006.2010.01675.x
[25]
L. Aloia, S. Parisi, L. Fusco
Differentiation of embryonic stem cells 1 (Dies1) is a component of bone morphogenetic protein 4 (BMP4) signaling pathway required for proper differentiation of mouse embryonic stem cells
J Biol Chem, 285 (2010), pp. 7776-7783 http://dx.doi.org/10.1074/jbc.M109.077156
[26]
K. Jung, I. Choi
Emerging co-signaling networks in T cell immune regulation
Immune Network, 13 (2013), pp. 184-193 http://dx.doi.org/10.4110/in.2013.13.5.184
[27]
C.S. Brandt, M. Baratin, E.C. Yi
The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans
J Exp Med, 206 (2009), pp. 1495-1503 http://dx.doi.org/10.1084/jem.20090681
[28]
T. Zhang, M.R. Wu, C.L. Sentman
An NKp30-based chimeric antigen receptor promotes T-cell effector functions and anti-tumor efficacy in vivo
J Immunol, 189 (2012), pp. 2290-2299 http://dx.doi.org/10.4049/jimmunol.1103495
[29]
Y. Zhu, S. Yao, B.P. Iliopoulou
B7-H5 costimulates human T cells via CD28H
Nat Commun, 4 (2013), pp. 1-12
[30]
B. Pope, R.D. Brown, J. Gibson
B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy
Blood, 96 (2000), pp. 1274-1279
Copyright © 2016. Sociedad Médica del Hospital General de México
es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.